Femasys (NASDAQ:FEMY) Posts Quarterly Earnings Results, Beats Expectations By $0.07 EPS

Femasys (NASDAQ:FEMY) announced its quarterly earnings results on Tuesday. The company reported ($0.01) EPS for the quarter, beating the consensus estimate of ($0.08) by $0.07, FiscalAI reports. Femasys had a negative return on equity of 764.26% and a negative net margin of 960.80%.The business had revenue of $0.81 million during the quarter, compared to analysts’ expectations of $1.06 million.

Femasys Stock Up 11.8%

FEMY opened at $0.42 on Wednesday. The firm has a market cap of $25.38 million, a P/E ratio of -0.58 and a beta of -2.53. The company has a debt-to-equity ratio of 0.01, a quick ratio of 0.61 and a current ratio of 1.16. The business has a 50 day moving average price of $0.54 and a 200 day moving average price of $0.63. Femasys has a twelve month low of $0.31 and a twelve month high of $1.34.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on FEMY. Weiss Ratings reiterated a “sell (e+)” rating on shares of Femasys in a research note on Thursday, January 22nd. Wall Street Zen lowered shares of Femasys from a “hold” rating to a “sell” rating in a research note on Saturday. Finally, Lake Street Capital initiated coverage on shares of Femasys in a research note on Tuesday, March 3rd. They issued a “buy” rating and a $1.50 price objective for the company. Four research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $5.50.

Institutional Trading of Femasys

A number of institutional investors and hedge funds have recently modified their holdings of FEMY. Geode Capital Management LLC raised its holdings in Femasys by 50.8% in the 4th quarter. Geode Capital Management LLC now owns 389,280 shares of the company’s stock worth $224,000 after acquiring an additional 131,052 shares during the period. Banco BTG Pactual S.A. bought a new stake in Femasys during the fourth quarter valued at about $88,000. Jane Street Group LLC bought a new stake in Femasys during the fourth quarter valued at about $62,000. State Street Corp grew its position in shares of Femasys by 43.5% in the fourth quarter. State Street Corp now owns 80,869 shares of the company’s stock valued at $47,000 after purchasing an additional 24,500 shares during the last quarter. Finally, Cetera Investment Advisers bought a new position in shares of Femasys in the fourth quarter worth about $36,000. 65.27% of the stock is currently owned by institutional investors and hedge funds.

Femasys Company Profile

Femasys International, Inc is a medical device company focused on the research, development and commercialization of innovative technologies for interventional women’s health applications. The company’s core activities center on creating minimally invasive diagnostic and therapeutic products designed to address uterine cavity evaluation and treatment and to improve outcomes in gynecological care.

The company’s flagship product, the FemVue® hydrosonography system, is a single-use catheter-based device that enhances visualization of the uterine cavity through saline infusion sonography.